Streetbeat News

Revenues

KYMR

Kymera Therapeutics (NASDAQ:KYMR) has been evaluated by 4 analysts in the past quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average price target is now $29.5, down from the previous $60.00, indicating a 50.83% decline. Analysts from Wells Fargo, Morgan Stanley, Piper Sandler, and HC Wainwright & Co. have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Kymera is a biotech company focused on targeted protein degradation to treat diseases. Despite a significant decline in revenue growth and below-average ROA, the company has a strong net margin and ROE, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

ACN

BCAN

CGEN

ETAO

MOTS

PBLA

ZJYL

U.S. stocks opened higher with the Dow Jones, NASDAQ, and S&P 500 all seeing gains. Materials shares led the market, while financial shares saw a slight decline. Accenture Plc (ACN) reported higher-than-expected Q1 earnings but provided a weaker sales forecast for Q2, expecting revenues to be lower than the consensus. Compugen Ltd. (CGEN), Panbela Therapeutics, Inc. (PBLA), and Jin Medical International Ltd. (ZJYL) saw significant stock price increases. Conversely, Motus GI Holdings, Inc. (MOTS), BYND Cannasoft Enterprises Inc. (BCAN), and ETAO International Co., Ltd. (ETAO) experienced notable declines in their share prices.

Portfolio Pulse from Avi Kapoor

December 19, 2023 | 2:42 pm

IGC

IGC Pharma, Inc. (NYSE:IGC) has received a patent in Mexico for its Alzheimer's treatment, 'Method and Composition for Treating CNS Disorder.' The company is conducting a Phase 2 trial for IGC-AD1, aimed at treating agitation in Alzheimer's patients. The patent is a key step towards potential commercialization in various jurisdictions, including the U.S. and Europe. Alzheimer's disease is a significant public health concern, with rising numbers and costs. IGC Pharma is developing multiple drug assets to address Alzheimer's-related agitation.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:29 pm

AMZN

Amazon Web Services (AWS) is planning a major reorganization of its sales team, led by Matt Garman, to address customer complaints and internal issues. The restructuring will consolidate teams to unify sales strategies and improve the assignment of technical staff to customers. This move comes as AWS faces increased competition from Microsoft and others, and aims to maintain its position as the leading cloud provider.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:11 pm

PPSI

Pioneer Power Solutions, Inc. (NASDAQ:PPSI) announced receiving three new orders totaling $3.1 million for its e-Boost mobile electric charging solutions. These orders are expected to contribute significantly to the company's revenue and operating margin in 2024. The orders include two from new customers and one reorder, showcasing the adoption and versatility of the e-Boost solutions across different platforms: Pod, Mobile, and Mini. Deliveries and installations are set to begin in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:08 pm

SCLX

Scilex Holding Company announced strong interest from rheumatologists in Gloperba, a liquid colchicine for gout prophylaxis, due to its precision dosing. Gloperba targets patients with comorbid conditions and those experiencing gastrointestinal side effects. Scilex, with a robust distribution network and experienced commercial team, is discussing dosing recommendations with the FDA. The gout treatment market is expected to reach $2.0 billion by 2028 in the U.S.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:03 pm

PNC

PNC Financial Services Group (NYSE:PNC) received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, 5 indifferent, 1 somewhat bearish, and 0 bearish. The average 12-month price target from 9 analysts is $141.04, up 7.5% from the previous $131.20. Analysts from firms like Goldman Sachs, Odeon Capital, and Piper Sandler have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. PNC's financial performance shows a revenue decline of -5.69%, a high net margin of 27.51%, a below-average ROE of 2.92%, an exceptional ROA of 0.26%, and a healthy debt-to-equity ratio of 1.34.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 2:01 pm

LII

Lennox Intl (NYSE:LII) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target among 10 analysts is $454.3, with a high of $550.00 and a low of $400.00. The current average target represents a 19.75% increase from the previous average of $379.38. Analysts from firms such as Wells Fargo, Stephens & Co., TD Cowen, Keybanc, Mizuho, Goldman Sachs, Barclays, and Morgan Stanley have raised their price targets for LII. Lennox International operates in the HVAC and refrigeration markets, with a focus on North America. The company has shown solid revenue growth but has a higher debt-to-equity ratio compared to the industry average.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 2:01 pm

ETN

Eaton Corp (NYSE:ETN) has been rated by 5 analysts in the last 3 months, with 2 somewhat bullish, 2 indifferent, and 1 somewhat bearish ratings. The average 12-month price target is $226.4, with a high of $257.00 and a low of $187.00. Over the past month, the average price target has increased by 5.92%. Analysts from Wells Fargo, RBC Capital, Barclays, JP Morgan, and Morgan Stanley have updated their ratings and price targets. Eaton is a diversified power management company with a strong market position, reflected in its financials, including a 10.67% revenue growth rate, a net margin of 15.15%, an ROE of 4.9%, an ROA of 2.41%, and a low debt-to-equity ratio of 0.52.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 2:00 pm

CCL

CRUZ

NCLH

RCL

Cruise line operators Carnival (CCL) and Royal Caribbean (RCL) have seen their shares more than double in 2023, with Carnival's stock up 128% and Royal Caribbean's up 145%. Norwegian Cruise Lines (NCLH) also gained 66%. The recovery is attributed to rising passenger numbers, lower oil prices, and the prospect of lower interest rates. Carnival's third-quarter revenues were the highest ever, driven by strong demand. The Defiance Hotel, Airline, and Cruise ETF (CRUZ), which includes cruise line operators, is up 33% year to date. However, Carnival noted rising input costs in its September quarterly results presentation, although oil prices have since fallen below $80 a barrel.

Portfolio Pulse from Neil Dennis

December 19, 2023 | 1:53 pm